The present invention relates to a pharmaceutical composition in a solid final dosage form comprising sirolimus exhibiting sufficient bioavailability and therapeutic effect, and a method for preparation thereof. A formulation with suitable therapeutic effect provides benefits in regard of cost reduction, process optimization and reduction in undesired effects regarding the formulation and its behavior in vivo